Background {#Sec1}
==========

Incomplete re-endothelialisation following stent implantation is strongly associated with stent thrombosis. Optical coherence tomography imaging (OCT) revealed an increased frequency of uncovered and/or malapposed stent struts, residual thrombus, and late pathological remodelling in lesions of ST segment elevation myocardial infarction (STEMI) compared with stable coronary artery disease patients at mid-term and long-term follow-up \[[@CR1]--[@CR3]\]. To date, only one OFDI study reported the arterial response in a head-to-head comparison between Absorb and everolimus-eluting stent (EES), in stable coronary artery disease \[[@CR4]\]. One year after implantation, the neointimal thickness and percentage in-device area obstruction were comparable between groups. On the other hand, the vascular response after Absorb BVS implantation seems similar to that observed with Xience EES at 6 months in this particular setting of STEMI \[[@CR5]\] but data concerning early re-endothelialisation remain scarce. The Synergy EES, which is now widely used, is made with biodegradable PLGA polymer, a platinum chromium scaffold, and thinner struts than the Xience and showed a particularly rapid endothelialisation in non-randomised preclinical studies \[[@CR6]\]. The purpose of this randomised, controlled, prospective pilot study was to compare the neointimal response of the Synergy EES and the Absorb BVS by OCT at 3 months after acute myocardial infarction (AMI).

Methods {#Sec2}
=======

Patients' enrolment and study design {#Sec3}
------------------------------------

The study design and protocol have been executed according to the SPIRIT 2013 Statement (see Additional file [1](#MOESM1){ref-type="media"} and Additional file [2](#MOESM2){ref-type="media"}: Figure S1). The study included patients presenting with STEMI with the following ECG criteria: at least 1 mm in two or more standard leads or at least 2 mm in two or more contiguous precordial leads, within the first 12 h after symptom onset, requiring emergent percutaneous coronary intervention (PCI) with a vessel size ranging between 2.25 and 3.8 mm and following adequate lesion preparation. The main exclusion criteria included cardiogenic shock, severe tortuosity, or calcification and inadequate vessel size (\< 2.25 or \> 3.80 mm). All patients were randomised 1:1 to one of two treatment arms (Synergy vs Absorb stent) using a sealed envelope technique. This study is an exploratory pilot study, with no hypothesis regarding the expected difference in strut coverage between the two groups. Hence, a number of 10 patients in each group has been arbitrarily set.

Randomisation was performed after establishment of at least TIMI 2 flow using sealed envelopes. Written informed consent was required and obtained from all patients prior to randomisation. Randomisation was performed by dedicated web-based software. Patients were blinded to the treatment. Our study received approval from our Medical Ethics Committee. The study was conducted in compliance with the protocol, the Declaration of Helsinki, and applicable local requirements.

Study endpoints {#Sec4}
---------------

The primary endpoint was the 3-month neointimal response assessed as the percentage of uncovered and/or malapposed struts, neointimal thickness, in-stent/scaffold area obstruction, and pattern of neointima \[[@CR7]--[@CR9]\]. For the coronary optical frequency domain imaging (OFDI) endpoint analysis, the stent area and derived measures were based on the abluminal stent contour \[[@CR10], [@CR11]\]. The main secondary clinical endpoints included device-oriented composite endpoint (DOCE; composite of cardiac death, target vessel myocardial infarction (MI), and clinically driven target lesion revascularisation (TLR)) at 3 and 12 months; the individual components of DOCE; device and procedural success, all-cause death; any myocardial infarction; non-clinically driven TLR; clinically indicated and non-clinically driven target vessel revascularisation; and stent thrombosis, as defined by the Academic Research Consortium \[[@CR12]\]. Reinfarction is defined according to the Third Universal Definition of MI as evidence of myocardial necrosis in a clinical setting consistent with acute MI \[[@CR13]\]. Device success was defined as the implantation of the assigned study device with post-procedure residual stenosis \< 30%. Procedure success was defined as device success without the occurrence of any component of the DOCE. Clinical follow-up was scheduled at 3 and 12 months. Angiographic follow-up was scheduled at 3 months.

Percutaneous coronary intervention procedure {#Sec5}
--------------------------------------------

Primary PCI and stent implantation were carried out in accordance with current standards \[[@CR14]\]. The Absorb stent was available in diameters of 2.5, 3.0, and 3.5 mm and in lengths of 8, 12, 18, and 28 mm. It was recommended to use similar sizes for the EES (Synergy; Boston Scientific). It was recommended that patients received a loading dose of aspirin and a P2Y12 inhibitor pre-procedure, followed by dual antiplatelet therapy for at least 12 months.

Angiographic and optical frequency domain imaging analysis {#Sec6}
----------------------------------------------------------

Angiographic endpoints at 3 months included percent diameter stenosis, minimal lumen diameter (MLD), and late lumen loss. All angiographic endpoints were assessed for the in-segment, in-device, proximal, and distal region. Optical frequency domain imaging endpoints were assessed at 3 months and included all individual components of the healing, the mean and minimal stent diameter, area and volume, the frequency of incomplete strut apposition including area and volume, the percentage of uncovered struts, the mean neointima thickness together with the neointimal hyperplasia area on top of the strut and inter-strut and volume, the mean flow area and volume, and the intraluminal defect area and volume.

Optical frequency domain imaging assessment of the stented coronary segment was performed using the Saint Jude console and the FastView catheter. Angiography and OCT recordings were sent to an independent Core Laboratory (Zwolle, the Netherlands) for off-line analysis.

Statistical analysis {#Sec7}
--------------------

Statistical analyses were performed using SPSS software, version 20.0 (SPSS Inc., Chicago, IL, USA), and Stata Software (Stata Statistical Software Release 10, College Station, TX, USA). Discrete variables are presented as counts and percentages, and continuous variables as means ± standard deviation (SD) when normally distributed and as median (interquartile range (IQR)) when non-normally distributed. Normally distributed data were compared using one-way analysis of variance or *t* tests, and non-normally distributed data were compared using the Mann--Whitney test. Categorical data were compared using Fisher's exact test or the chi-square test. A two-tailed *p* value of 0.05 was considered statistically significant.

Role of the funding source {#Sec8}
--------------------------

The trial was designed by the principal investigator. The trial was supported by unrestricted grants from Boston Scientific Corporation. The investigator funded an independent data management and analysis centre (Diagram, Zwolle, the Netherlands) for database management and all statistical analyses.

Results {#Sec9}
=======

Baseline clinical characteristics {#Sec10}
---------------------------------

A total of 22 lesions (12 treated with everolimus DES and 10 treated with everolimus BVS) in 22 patients was selected for the present study. Two patients in the Synergy group were excluded before 3-month OCT assessment for stent thrombosis and renal failure. All non-clinical and clinical outcomes data were collected from the 20 remaining patients. Baseline clinical characteristics were comparable among both groups (Table [1](#Tab1){ref-type="table"}). Procedural characteristics are presented in Table [2](#Tab2){ref-type="table"}. Thrombectomy was used in two patients (one in each group) and pre-dilatation was attempted in 65% of the population (9 out of 10 in the Absorb group vs 4 out of 10 in the Synergy group) without significant difference between the groups. Post-dilatation was more frequently performed in the Absorb arm (80 vs. 10%, *p* \< 0.005). On average, a total of 1.05 stents was implanted at the culprit lesion with a mean total length of 22.6 mm (± 5.3). The mean nominal diameter was larger in the Synergy arm (3.7 vs 3.4 mm, *p* = 0.01).Table 1Baseline clinical parametersAbsorb (*n* = 10)Synergy (*n* = 10)*pN* (%)*N* (%)Age (years)56.5 ± 13.6^a^61.4 ± 9.00.350Male9 (90.0)7 (70.0)0.582Treatment for hypertension3 (30.0)3 (30.0)1.000Treatment for hypercholesterolemia2 (20.0)0 (0.0)0.474Diabetes mellitus1 (10.0)0 (0.0)1.000Current smoking5 (50.0)4 (40.0)1.000MDRD clearance \< 60 ml/min/1.73 m^2^1 (10.0)1 (10.0)1.000Fasting plasma glucose ≥ 7 mmol/l3 (30.0)8 (80.0)0.070LVEF (%)52.5 ± 7.952.9 ± 10.30.923LAD significant lesion (\> 50%)9 (90.0)7 (70.0)0.582Cx significant lesion (\> 50%)5 (50.0)1 (10.0)0.141RCA significant lesion (\> 50%)5 (50.0)8 (80.0)0.350\> 1-vessel disease8 (80.0)6 (60.0)0.628*Cx* circumflex artery, *LAD* left anterior descending, *LVEF* left ventricular ejection fraction, *MDRD* Modification of Diet in Renal Disease, *RCA* right coronary artery^a^Mean ± standard deviation. *t* test used for comparisonsTable 2Procedural characteristicsIndex PCIAbsorb (*n* = 10)Synergy (*n* = 10)*pN* (%)*N* (%)Pre-dilatation9 (90.0)4 (40.0)0.057Post-dilatation8 (80.0)1 (10.0)0.005Vessel diameter (mm)3.4 ± 0.5^a^3.7 ± 0.40.118 Vessel \< 3.5 mm3 (30.0)1 (10.0)0.582Implanted stents1.000 One9 (90.0)10 (100) Two1 (10.0)0 (0)Stent(s) diameter3.3 ± 0.43.7 ± 0.40.010 Stent(s) \< 3.5 mm4 (40.0)1 (10.0)0.303Stent(s) length23.7 ± 5.221.6 ± 5.40.388*PCI* percutaneous coronary intervention^a^Mean ± standard deviation. *t* test used for comparisons

Procedural and quantitative angiographic characteristics {#Sec11}
--------------------------------------------------------

Angiographic characteristics are presented in Table [3](#Tab3){ref-type="table"}. The interpolated reference vessel diameter and diameter stenosis were higher in the Synergy arm with borderline significance. Post implantation, MLD was higher in the Synergy group (2.99 vs 2.41 mm, *p* = 0.02). At 3-month follow-up, the lumen loss tended to be lower for the Synergy device but the difference was not significant (0.03 mm (IQR 0.00--0.07 mm) vs 0.11 mm (IQR 0.04--0.31 mm), *p* = 0.165).Table 3Quantitative coronary arteriography (QCA) results post implantation and at 3-month follow-upOverall (*n* = 20)Absorb (*n* = 10)Synergy (*n* = 10)*pN* (%)*N* (%)*N* (%)Vessel0.141 RCA12 (60%)4 (40%)8 (80%) LAD6 (30%)5 (50%)1 (10%) Cx2 (10%)1 (10%)1 (10%)QCA post implantation Lesion length18.51 ± 5.19^a^16.77 ± 3.7220.25 ± 6.010.137 Interpolated RVD3.05 ± 0.542.82 ± 0.493.28 ± 0.500.056 MLD2.71 ± 0.572.42 ± 0.602.99 ± 0.380.020 Diameter stenosis11.70 ± 8.3715.20 ± 9.508.20 ± 5.510.059QCA at follow-up Lesion length18.73 ± 5.2617.43 ± 3.9720.02 ± 6.250.284 Interpolated RVD2.91 ± 0.522.66 ± 0.503.21 ± 0.370.020 MLD2.59 ± 0.592.22 ± 0.602.95 ± 0.260.003 Diameter stenosis13.39 ± 10.517.90 ± 11.657.75 ± 5.500.038 Late lumen loss0.05 (0.02--0.31)^b^0.11 (0.04--0.31)0.03 (0.00--0.07)0.165*Cx* circumflex artery, *LAD* left anterior descending, *MLD* minimal lumen diameter, *RCA* right coronary artery^a^Mean ± standard deviation. *t* test used for comparisons^b^Median (interquartile range). Mann--Whitney test used for comparisons

Quantitative OCT findings at 3-month follow-up {#Sec12}
----------------------------------------------

Table [4](#Tab4){ref-type="table"} presents the quantitative OCT findings at lesion-level analysis. The Synergy DES presented with a higher minimal lumen area (7.73 ± 2.12 mm^2^ vs 5.07 ± 2.00 mm^2^, *p* = 0.01) and a higher endoluminal stent area (8.13 ± 2.19 mm^2^ vs 5.39 ± 1.87 mm^2^, *p* = 0.008) than the everolimus BVS at 3-month follow-up. The Fig. [1](#Fig1){ref-type="fig"} illustrates distribution of in-stent/scaffold area obstruction and neointimal thickness among the 2 groups. Table 4Stent-level analysisAbsorb (*n* = 10)Synergy (*n* = 10)*pN* (%)*N* (%)ROI length (mm)23.28 ± 4.25^a^21.03 ± 6.390.366Proximal reference lumen area (mm^2^)7.94 ± 2.8911.15 ± 3.570.053Distal reference lumen area (mm^2^)7.85 ± 2.969.65 ± 3.220.209Minimal lumen area (mm^2^)5.07 ± 2.007.73 ± 2.120.010Endoluminal neointimal17.46 ± 6.9114.42 ± 4.720.266stent/scaffold volume (mm^3^)Abluminal neointimal + stent/scaffold strut volume (mm^3^)44.34 ± 14.2733.57 ± 10.940.074Abluminal stent area (mm^2^)7.03 ± 2.049.48 ± 2.470.027Endoluminal stent area (mm^2^)5.39 ± 1.878.13 ± 2.190.008Malapposition volume \> 0 mm^3^2 (20%)3 (30%)1.000Stent/scaffold with \> 30% area stenosis3 (30%)0 (0%)0.211% area stenosis18.4 + 15.87.6 ± 7.50.067Neointimal thickness (mm)0.04 (0.03--0.05)^b^0.05 (0.04--0.06)0.385Maximal neointimal thickness (mm)0.209 (0.173--0.245)0.220 (0.140--0.260)0.880Maximal in-stent/scaffold obstruction (%)11.5 (10--13)11.5 (10--14)0.970In-stent/scaffold obstruction (%)7.89 (6.84--9.42)6.98 (6.26--7.33)0.112Neointima Homogeneous6 (60%)30 (30%) Heterogeneous4 (40%)70 (70%)0.370 Disrupted stent/scaffold1 (10%)01.000^a^Mean ± standard deviation^b^Median (interquartile range)*ROI* region of interestFig. 1Histogram distribution of the in-stent/scaffold area obstruction and comparative neointimal thickness with DES vs BVS stents. **a** Histogram distribution of in-stent/scaffold area obstruction (%) per cross-sectional level (420 cross-sections). Everolimus drug-eluting stents (DES) had median (interquartile range) of 6.4% (5.2--8.4%) and everolimus bioresorbable vascular scaffolds (BVS) had median of 7.9% (6.6--10.5%), *p* \<  0.001. **b** Histogram distribution of neointimal thickness at strut level (3942 struts). Everolimus DES had mean neointimal thickness (± SD) of 0.046 ± 0.038 mm and everolimus BVS had mean (± SD) of 0.061 ± 0.062 mm, *p* \<  0.001

Table [5](#Tab5){ref-type="table"} presents the OCT results at cross-sectional (420 cross-sections analysed) and strut (3942 struts analysed) levels. At the cross-sectional level, a higher total neointimal area (1.94 ± 0.57 mm^2^ vs 1.76 ± 0.60 mm^2^) as well as a higher in-stent/scaffold obstruction (9.6 ± 4.8% vs 7.0 ± 2.5%, *p* \< 0.001) were observed in the Absorb arm. At the strut level, the neointimal thickness per strut (NIT) was lower in the Synergy group, even when 4-mm-diameter Synergy stents were excluded. Finally, at the patient level (Table [4](#Tab4){ref-type="table"}), area stenosis tended to be lower with the everolimus DES (7.6 ± 7.5%) than with the everolimus BVS (18.4 ± 15.8%, *p* = 0.07).Table 5Cross-sectional and stent strut-level analysisAll patients (*n* = 20)Stent diameter \< 4 mm^a^ (*n* = 15)*N* (%)*N* (%)*pN* (%)*N* (%)*p*Cross-sectional analysis (number of struts)Absorb (229)Synergy (191)Absorb (229)Synergy (89) Lumen area (mm^2^)6.61 ±  2.12^b^9.48 ±  2.50\< 0.0016.61 ±  2.127.67 ±  1.67\< 0.001 Adluminal stent/scaffold area (mm^2^)8.52 ±  2.1511.23 ±  2.72\< 0.0018.52 ±  2.159.32 ± 1.740.002 Endoluminal stent/scaffold area (mm^2^)6.65 ±  2.019.72 ±  2.48\< 0.0016.65 ±  2.018.00 ±  1.60\< 0.001 Endoluminal neointimal area (mm^2^)0.76 ±  0.290.76 ±  0.250.7890.76 ±  0.290.73 ±  0.200.336 Abluminal neointimal area + stent/scaffold strut area (mm^2^)1.94 ±  0.571.76 ±  0.600.0021.94 ±  0.571.65 ±  0.35\< 0.001 Neointima  Homogeneous213 (93%)162 (85%)213 (93%)79 (89%)  Heterogeneous16 (7%)29 (15%)0.00716 (7%)10 (11%)0.214 Cross-section with intraluminal mass3 (1.3%)2 (1.1%)1.0003 (1.3%)2 (2.3%)0.622 Cross-section with malapposition area \> 07 (3.1%)6 (3.1%)0.9607 (3.1%)0 (0.0%)0.098 Cross-section with uncovered struts43 (19%)45 (24%)0.23043 (19%)19 (21%)0.603 Cross-section with malapposed and uncovered struts01 (0.5%)0.45500 (0.0%) In stent/scaffold obstruction (%)9.59 ± 4.817.01 ± 2.52\< 0.0019.59 ±  4.818.12 ±  2.730.007Stent strut level analysisAbsorb (2062)Synergy (1880)Absorb (2062)Synergy (778) Uncovered struts (*n*, %)47 (2.3%)143 (7.6%)\< 0.00147 (2.3%)30 (3.9%)0.021 Malapposed struts (*n*, %)7 (0.3%)23 (1.2%)0.0017 (0.3%)1 (0.1%)0.692 Malapposed and uncovered (*n*, %)0 (0.0%)4 (0.2%)0.0520 (0.0%)0 (0.0%) Neointimal thickness per strut (mm^2^)0.06 ± 0.060.05 ± 0.04\< 0.0010.06 ± 0.060.05 ± 0.03\< 0.001^a^Five patients with Synergy 4-mm-diameter stent excluded^b^Mean ± standard deviation. *t test* used for comparisons

Qualitative OCT findings at 3-month follow-up {#Sec13}
---------------------------------------------

Figure [2](#Fig2){ref-type="fig"} and Table [5](#Tab5){ref-type="table"} present qualitative and quantitative OCT findings at 3-month follow-up. All struts had a preserved box appearance. At the strut level, the proportion of uncovered struts was lower in the Absorb arm (2.3% vs 7.6%, *p* \< 0.001) and the difference was still significant when high-diameter Synergy stents were excluded. The proportion of malapposed struts was also higher in the Synergy group than in the Absorb group (1.2% vs 0.3% respectively, *p* \< 0.001), but the difference did not remain when patients with high-diameter Synergy stents were excluded. There was a statistically significant trend to a higher rate of heterogeneous pattern of tissue coverage with the everolimus DES than with the everolimus BVS (15% vs 7%, *p* \<  0.007).Fig. 2Qualitative OCT findings at 3-month follow-up. **a** Homogeneous neointima which covers Absorb (Abbott Vascular, Santa Clara, CA, USA) struts. **b** Heterogeneous neointima of Absorb (arrow). **c** Uncovered malapposed strut of Absorb (arrow). **d** Homogeneous neointima which covers the Synergy (Boston Scientific, Marlborough, MA, USA) struts, with two uncovered (arrows). **e** Heterogeneous neointima which covers Synergy struts (arrow). **f** Malapposed struts of covered (white arrows) and uncovered (green arrows) Synergy struts

Clinical outcomes {#Sec14}
-----------------

Among the 20 patients who remained in the study until completion, device success was achieved in 19 patients (one patient in the BVS group had a residual stenosis of 32% post implantation). DOCE occurred in two patients (one patient in each group) subsequent to myocardial infarction. Two patients from the BVS group had a non-clinically driven TLR.

Between the 3-month and 12-month follow-up, no cardiac symptoms were observed. All 20 patients were alive at 1-year follow-up.

Discussion {#Sec15}
==========

This trial is the first randomised clinical trial that compared the Absorb stent with the non-erodible metallic everolimus DES (Synergy with biodegradable polymer) while investigating stenting of culprit lesions in the setting of STEMI. Ideally, patients presenting with STEMI would represent the best scenario for using Absorb stents. Culprit lesions are frequently localised in the proximal segments of the coronary artery tree. Therefore, restoration of physiological vasomotion may have a greater effect in patients with STEMI, compared to patients with stable coronary artery disease. Finally, the potential advantages of implanting Absorb (vs other DES) in STEMI may be mostly related to the young age of these patients. Current evidence about the use of Absorb in STEMI remains scarce and limited to few registries that enlisted a low number of patients \[[@CR15]\]. Recently, the results of the "ABSORB II" trial at 3-year follow-up, which only included non-MI patients \[[@CR16]\], showed a higher rate of device-oriented composite endpoint in the Absorb group. Indeed, real-world randomised trials, observational registries, and meta-analysis suggest an approximate 3-fold incremental increase in scaffold thrombosis rates beyond 1 year after implantation of the Absorb BVS compared to the benchmark metal drug-eluting model \[[@CR17]\]. On the other hand, the Synergy stent consists of a thin strut, balloon-expandable platinum--chromium stent platform delivering everolimus from an ultrathin (4 μm) bioabsorbable PLGA polymer applied to the abluminal surface \[[@CR18]\]. Consequently, it was interesting to evaluate the very early re-endothelialisation of the Synergy stent vs the Absorb BVS in the setting of acute myocardial infarction. The principal findings can be summarised as follows: stent endothelisation on the basis of strut coverage was nearly complete for both devices, with more than 90% of covered struts at 3 months; after 3 months, the response of the arterial wall observed after stenting was different between the two groups, with lower neointimal thickness and in-stent obstruction in the Synergy group but with a lower rate of uncovered struts in the BVS group; the frequency of malapposed struts was lower in the Absorb arm; and at 3 months, late lumen loss tended to be lower in the Synergy arm.

In order to reduce the effect of stent diameter, OCT findings at 3 months were presented in the whole sample, but also after exclusion of patients treated with 4 mm-diameter Synergy stents. In both of these analyses, better results were obtained with Synergy stents in terms of lumen area and neointimal thickness of in-stent obstruction, but better results were obtained with BVS devices in terms of uncovered struts. Finally, our results suggest that the over-frequency of target-lesion failure or stent thrombosis observed with BVS in the Absorb III trial \[[@CR19]\] may not be attributable to differences in endothelisation.

Our findings are significant for several other reasons. Rupture plaques in patients with STEMI have been shown to be prone to delayed arterial healing. Specifically, the mean rate of uncovered stents appeared to be as high as 49% in culprit lesions from STEMI, as compared to 9% in stable plaques after first-generation DES implantation \[[@CR1]\]. The advent of second-generation DES has improved the arterial healing response. In an in vivo animal model, the use of everolimus eluting stent (EES) compared to first-generation sirolimus-eluting stent was associated with a lower incidence of uncovered struts and a minimal degree of inflammatory reaction \[[@CR20]\]. These findings have been corroborated in humans in whom EES evidenced lower frequencies of uncovered struts and malapposed struts compared with paclitaxel-eluting stent \[[@CR21]\], as assessed by OCT. Our results are promising, as they were obtained over a shorter follow-up period (3 months) and in the context of high thrombogenic milieu. Post implantation, MLD was higher in the Synergy group due to the absence of 4-mm-diameter stents in the Absorb group. Moreover, the higher post-dilatation approach in the Absorb trial (PSP technic) may explain the lower rate of uncovered and/or malapposed struts in this group. However, these two limitations do not modify the neointimal thickness and in-stent/scaffold area obstruction at 3-month follow-up. Finally, late loss was not significantly different between groups (0.10 vs 0.03 mm in the EES arm, *p* = 0.165).

Study limitations {#Sec16}
=================

The study limitations include a monocentric trial and a low rate of events, which may be related to highly selective enrolment criteria (only non-complicated STEMI patients admitted during the recruitment period were included), inclusion and exclusion criteria, the requirement for patients' consent in the acute phase of STEMI, the randomisation requirement after successful lesion preparation, and the requirement for an angiographic follow-up. Thus, the results presented herein cannot be representative of a more complex population suffering from STEMI.

Secondly, our study assessed arterial healing at 3 months, which is an intermediate time point when the resorption process is not complete and the process of neointima formation in EES has not yet occurred. A longer-term follow-up is needed to further characterise the healing process. Thirdly, healing-related results refer to the new Synergy stent technology and cannot be extrapolated to other bioresorbable devices with different materials or strut thickness. Finally, this randomised trial was an exploratory pilot study. In the absence of previous data on early re-endothelialisation after STEMI in the Synergy group, no hypothesis could be formulated on the differences to be expected in strut coverage between both groups at the time of the study design, and power computations were not possible.

Conclusions {#Sec17}
===========

In this randomised trial conducted in the setting of MI, endothelisation was nearly complete with both the Synergy and the BVS devices. Some discrepancies were observed in the strut coverage rate (in favour of BVS) or in neointimal thickness (in favour of Synergy). This trial provides the basis for further exploration in clinical outcomes trials.
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